Sevelamer in Proteinuric CKD

Summary

Sevelamer in Proteinuric CKD is a clinical trial^[1].

Key Facts

• Sevelamer in Proteinuric CKD is in the country of Italy^[2].
• Sevelamer in Proteinuric CKD's instance of is recorded as clinical trial^[3].
• Sevelamer in Proteinuric CKD's start time is recorded as +2013-10-31T00:00:00Z^[4].
• Sevelamer in Proteinuric CKD's end time is recorded as +2015-10-31T00:00:00Z^[5].
• Sevelamer in Proteinuric CKD's sponsor is recorded as Mario Negri Institute for Pharmacological Research^[6].
• Sevelamer in Proteinuric CKD's main subject is recorded as end stage renal failure^[7].
• Sevelamer in Proteinuric CKD's number of participants is recorded as {'unit': '1', 'amount': '+53'}^[8].
• Sevelamer in Proteinuric CKD's title is recorded as A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment^[9].
• Sevelamer in Proteinuric CKD's short name is recorded as ANSWER^[10].
• Sevelamer in Proteinuric CKD's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Sevelamer in Proteinuric CKD's ClinicalTrials.gov ID is recorded as NCT01968759^[12].
• Sevelamer in Proteinuric CKD's research intervention is recorded as ramipril^[13].
• Sevelamer in Proteinuric CKD's research intervention is recorded as irbesartan^[14].
• Sevelamer in Proteinuric CKD's research intervention is recorded as sevelamer^[15].
• Sevelamer in Proteinuric CKD's clinical trial phase is recorded as phase II clinical trial^[16].
• Sevelamer in Proteinuric CKD's research subject recruitment status is recorded as completed^[17].
• Sevelamer in Proteinuric CKD's study type is recorded as interventional study^[18].